| Indication |
For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma |
| Pharmacodynamics |
Methazolamide is topical carbonic anhydrase inhibitor.
Methazolamide is indicated for the reduction of elevated intraocular
pressure in patients with open-angle glaucoma or ocular hypertension who
are insufficiently responsive to beta-blockers. Methazolamide is a
sulfonamide derivative; however, it does not have any clinically
significant antimicrobial properties. Although methazolamide achieves a
high concentration in the cerebrospinal fluid, it is not-considered an
effective anticonvulsant. Methazolamide has a weak and transient
diuretic effect, therefore use results in an increase in urinary volume,
with excretion of sodium, potassium and chloride. |
| Mechanism of action |
Methazolamide is a potent inhibitor of carbonic anhydrase.
Inhibition of carbonic anhydrase in the ciliary processes of the eye
decreases aqueous humor secretion, presumably by slowing the formation
of bicarbonate ions with subsequent reduction in sodium and fluid
transport. |
| Absorption |
Methazolamide is well absorbed from the gastrointestinal tract. |
| Volume of distribution |
|
| Protein binding |
55% |
| Metabolism |
Not Available |
| Route of elimination |
Not Available |
| Half life |
14 hours |
| Clearance |
Not Available |
| Toxicity |
Electrolyte imbalance, development of an acidotic state, and
central nervous system effects might be expected to occur in the case of
an overdose. |
Comments
Post a Comment